Sequel MedTech

Sequel MedTech is a medical technology company dedicated to simplifying the management of diabetes through innovative automated insulin delivery (AID) solutions. The company's flagship product, the twine system, is an all-in-one wearable insulin pump that received FDA clearance in May 2024 for individuals aged two and older with type 1 diabetes. Developed in partnership with DEKA Research & Development, the twine system utilizes advanced algorithms to automate insulin dosing based on real-time glucose data from continuous glucose monitors. By integrating the pump and controller into a single discreet device, Sequel MedTech aims to reduce the daily burden and complexity associated with diabetes care. The company is led by experienced healthcare executives and focuses on expanding access to life-changing medical technologies through user-centric design.